193 related articles for article (PubMed ID: 32920198)
1. Orally available tubulin inhibitor VERU-111 enhances antitumor efficacy in paclitaxel-resistant lung cancer.
Mahmud F; Deng S; Chen H; Miller DD; Li W
Cancer Lett; 2020 Dec; 495():76-88. PubMed ID: 32920198
[TBL] [Abstract][Full Text] [Related]
2. An Orally Available Tubulin Inhibitor, VERU-111, Suppresses Triple-Negative Breast Cancer Tumor Growth and Metastasis and Bypasses Taxane Resistance.
Deng S; Krutilina RI; Wang Q; Lin Z; Parke DN; Playa HC; Chen H; Miller DD; Seagroves TN; Li W
Mol Cancer Ther; 2020 Feb; 19(2):348-363. PubMed ID: 31645441
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic efficacy of a novel βIII/βIV-tubulin inhibitor (VERU-111) in pancreatic cancer.
Kashyap VK; Wang Q; Setua S; Nagesh PKB; Chauhan N; Kumari S; Chowdhury P; Miller DD; Yallapu MM; Li W; Jaggi M; Hafeez BB; Chauhan SC
J Exp Clin Cancer Res; 2019 Jan; 38(1):29. PubMed ID: 30674344
[TBL] [Abstract][Full Text] [Related]
4. Colchicine Binding Site Agent DJ95 Overcomes Drug Resistance and Exhibits Antitumor Efficacy.
Arnst KE; Wang Y; Lei ZN; Hwang DJ; Kumar G; Ma D; Parke DN; Chen Q; Yang J; White SW; Seagroves TN; Chen ZS; Miller DD; Li W
Mol Pharmacol; 2019 Jul; 96(1):73-89. PubMed ID: 31043459
[TBL] [Abstract][Full Text] [Related]
5. BZML, a novel colchicine binding site inhibitor, overcomes multidrug resistance in A549/Taxol cells by inhibiting P-gp function and inducing mitotic catastrophe.
Bai Z; Gao M; Zhang H; Guan Q; Xu J; Li Y; Qi H; Li Z; Zuo D; Zhang W; Wu Y
Cancer Lett; 2017 Aug; 402():81-92. PubMed ID: 28576750
[TBL] [Abstract][Full Text] [Related]
6. A novel orally active microtubule destabilizing agent S-40 targets the colchicine-binding site and shows potent antitumor activity.
Du T; Lin S; Ji M; Xue N; Liu Y; Zhang Z; Zhang K; Zhang J; Zhang Y; Wang Q; Sheng L; Li Y; Lu D; Chen X; Xu H
Cancer Lett; 2020 Dec; 495():22-32. PubMed ID: 32931884
[TBL] [Abstract][Full Text] [Related]
7. A Potent, Metabolically Stable Tubulin Inhibitor Targets the Colchicine Binding Site and Overcomes Taxane Resistance.
Arnst KE; Wang Y; Hwang DJ; Xue Y; Costello T; Hamilton D; Chen Q; Yang J; Park F; Dalton JT; Miller DD; Li W
Cancer Res; 2018 Jan; 78(1):265-277. PubMed ID: 29180476
[TBL] [Abstract][Full Text] [Related]
8. Orally bioavailable tubulin antagonists for paclitaxel-refractory cancer.
Li CM; Lu Y; Chen J; Costello TA; Narayanan R; Dalton MN; Snyder LM; Ahn S; Li W; Miller DD; Dalton JT
Pharm Res; 2012 Nov; 29(11):3053-63. PubMed ID: 22760659
[TBL] [Abstract][Full Text] [Related]
9. 5-(3,4,5-trimethoxybenzoyl)-4-methyl-2-(p-tolyl) imidazol (BZML) targets tubulin and DNA to induce anticancer activity and overcome multidrug resistance in colorectal cancer cells.
Bai Z; Liu X; Guan Q; Ding N; Wei Q; Tong B; Zhao M; Zhang W; Ma L
Chem Biol Interact; 2020 Jan; 315():108886. PubMed ID: 31682804
[TBL] [Abstract][Full Text] [Related]
10. Preclinical pharmacologic evaluation of MST-997, an orally active taxane with superior in vitro and in vivo efficacy in paclitaxel- and docetaxel-resistant tumor models.
Sampath D; Greenberger LM; Beyer C; Hari M; Liu H; Baxter M; Yang S; Rios C; Discafani C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3459-69. PubMed ID: 16740771
[TBL] [Abstract][Full Text] [Related]
11. A Novel Nitrobenzoate Microtubule Inhibitor that Overcomes Multidrug Resistance Exhibits Antitumor Activity.
Zheng YB; Gong JH; Liu XJ; Wu SY; Li Y; Xu XD; Shang BY; Zhou JM; Zhu ZL; Si SY; Zhen YS
Sci Rep; 2016 Aug; 6():31472. PubMed ID: 27510727
[TBL] [Abstract][Full Text] [Related]
12. SB226, an inhibitor of tubulin polymerization, inhibits paclitaxel-resistant melanoma growth and spontaneous metastasis.
Deng S; Banerjee S; Chen H; Pochampally S; Wang Y; Yun MK; White SW; Parmar K; Meibohm B; Hartman KL; Wu Z; Miller DD; Li W
Cancer Lett; 2023 Feb; 555():216046. PubMed ID: 36596380
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma.
Mundra V; Peng Y; Kumar V; Li W; Miller DD; Mahato RI
Drug Deliv Transl Res; 2015 Jun; 5(3):199-208. PubMed ID: 25924699
[TBL] [Abstract][Full Text] [Related]
14. The Design, Synthesis, and Biological Activities of Pyrrole-Based Carboxamides: The Novel Tubulin Inhibitors Targeting the Colchicine-Binding Site.
Boichuk S; Galembikova A; Syuzov K; Dunaev P; Bikinieva F; Aukhadieva A; Zykova S; Igidov N; Gankova K; Novikova M; Kopnin P
Molecules; 2021 Sep; 26(19):. PubMed ID: 34641324
[TBL] [Abstract][Full Text] [Related]
15. Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.
Zang F; Rao Y; Zhu X; Wu Z; Jiang H
Mol Med; 2020 Apr; 26(1):28. PubMed ID: 32268876
[TBL] [Abstract][Full Text] [Related]
16. MT-4 suppresses resistant ovarian cancer growth through targeting tubulin and HSP27.
Pai HC; Kumar S; Shen CC; Liou JP; Pan SL; Teng CM
PLoS One; 2015; 10(4):e0123819. PubMed ID: 25874627
[TBL] [Abstract][Full Text] [Related]
17. A novel synthetic compound exerts effective anti-tumour activity in vivo via the inhibition of tubulin polymerisation in A549 cells.
Yan J; Pang Y; Sheng J; Wang Y; Chen J; Hu J; Huang L; Li X
Biochem Pharmacol; 2015 Sep; 97(1):51-61. PubMed ID: 26212540
[TBL] [Abstract][Full Text] [Related]
18. Synergistic combination of novel tubulin inhibitor ABI-274 and vemurafenib overcome vemurafenib acquired resistance in BRAFV600E melanoma.
Wang J; Chen J; Miller DD; Li W
Mol Cancer Ther; 2014 Jan; 13(1):16-26. PubMed ID: 24249714
[TBL] [Abstract][Full Text] [Related]
19. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells.
Lee WH; Liu HE; Chang JY; Liou JP; Huang HM
Pharmacology; 2013; 92(1-2):90-8. PubMed ID: 23949011
[TBL] [Abstract][Full Text] [Related]
20. Targeting heat shock protein 90 with CUDC-305 overcomes erlotinib resistance in non-small cell lung cancer.
Bao R; Lai CJ; Wang DG; Qu H; Yin L; Zifcak B; Tao X; Wang J; Atoyan R; Samson M; Forrester J; Xu GX; DellaRocca S; Borek M; Zhai HX; Cai X; Qian C
Mol Cancer Ther; 2009 Dec; 8(12):3296-306. PubMed ID: 19952121
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
